CluenexBecton, Dickinson and Company BDX
Becton, Dickinson and Company scores average on business quality (4.6 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Becton, Dickinson and Company does
Becton Dickinson sells medical devices, instrument systems, and reagents to healthcare institutions globally. Hospitals and clinics rely on its core consumables for daily clinical workflows.
- What it does best
BDX dominates high-volume medical consumable manufacturing, anchoring hospital supply chains with essential syringes and catheters. Its gross margin sits at 46.7%, trailing peer ISRG at 66.7% due to heavy reliance on lower-margin hardware.
- The main risk
Heavy debt loads create structural vulnerability, with net debt at $18.5 billion and interest coverage standing at 5.8x. Higher borrowing costs directly compress net income, leaving little room for operational missteps.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin lands at 16.3% with net margin at 4.5%, showing thin conversion of revenue into bottom-line profit. Profitability remains constrained by high cost structures relative to peers.
Scale and entrenched hospital relationships form its moat, locking in institutional buyers through sheer supply chain ubiquity. Its gross margin sits in the bottom quartile at the 25th sector percentile.
Revenue grew 8.2% to $20.8B, marking a steady recovery from prior years. Growth tracks near the middle of its sector at the 48th percentile.
Net debt sits at $18.5 billion alongside interest coverage of 5.8x, meaning debt costs claim a meaningful slice of earnings. Free cash flow reached $2.6B, showing softer generation than historical peaks.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
1 sold $441K outside pre-planned sales.
Our sealed record on BDX
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Becton, Dickinson and Company scores average on the Cluenex quality check (4.6 of 10), measured against its own industry. Profitability is weak, moat fair, growth steady and financial health fair.
In the last 90 days of SEC Form 4 filings: 1 sold $441K outside pre-planned sales.
Nov 5, 2026, after the close.
See BDX today
- Today's verdict on BDX, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Becton, Dickinson and Company (BDX)”, https://cluenex.com/stocks/bdx/, data as of Oct 10, 2026.